by admin | Oct 16, 2023 | Press Release
— Orally delivered biologic drug to treat and prevent C. difficile infection to start recruiting for late-stage trials in Q4 2023 Seattle, WA, October 17, 2023 – Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent...
by admin | Oct 11, 2023 | Press Release
Seattle-based biotech company Lumen Bioscience is working to reduce atmospheric harm by reducing cows’ methane emissions. The company is developing a manufactured enzyme to prevent cows’ digestive microorganisms from producing methane. Although Lumen typically makes...
by admin | Oct 4, 2023 | Press Release
Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature...
by admin | Oct 2, 2023 | Press Release
The University of Utah’s Wilkes Climate Center has awarded its first $1.5 million climate prize to a Seattle biotech firm, Lumen Bioscience, that has developed and patented enzymes that could potentially halve the climate-damaging methane that cows belch all day....
4 ideas to kick-start U.S. drug research — and beat China in biotech
Revolutionizing the Production of Biologics with Algae
Past Wilkes Prize winners accelerate audacious climate solutions
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota